Healthcare Cost Impact of Continued Anticoagulation with Rivaroxaban versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the EINSTEIN-CHOICE Trial Population

Philip S. Wells, Martin H. Prins, Jan Beyer-Westendorf, Anthonie WA. Lensing, Lloyd Haskell, Bennett Levitan, François Laliberté, Veronica Ashton, Yongling Xiao, Dominique Lejeune, Concetta Crivera, Patrick Lefebvre, Qi Zhao, Zhong Yuan, Jeff Schein, Paolo Prandoni

    Research output: Contribution to journal › Article › peer-review

    5 Citations (Scopus)
    163 Downloads (Pure)

    Fingerprint

    Dive into the research topics of 'Healthcare Cost Impact of Continued Anticoagulation with Rivaroxaban versus Aspirin for Prevention of Recurrent Symptomatic Venous Thromboembolism in the EINSTEIN-CHOICE Trial Population'. Together they form a unique fingerprint.

    Pharmacology, Toxicology and Pharmaceutical Science